<?xml version="1.0"?>
<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1/"><rdf:Description rdf:about="https://repozitorij.uni-lj.si/IzpisGradiva.php?id=142961"><dc:title>Discovery of a fragment hit compound targeting D-Ala:D-Ala ligase of bacterial peptidoglycan biosynthesis</dc:title><dc:creator>Proj,	Matic	(Avtor)
	</dc:creator><dc:creator>Hrast Rambaher,	Martina	(Avtor)
	</dc:creator><dc:creator>Bajc,	Gregor	(Avtor)
	</dc:creator><dc:creator>Frlan,	Rok	(Avtor)
	</dc:creator><dc:creator>Meden,	Anže	(Avtor)
	</dc:creator><dc:creator>Butala,	Matej	(Avtor)
	</dc:creator><dc:creator>Gobec,	Stanislav	(Avtor)
	</dc:creator><dc:subject>fragment-based drug discovery</dc:subject><dc:subject>hit triage</dc:subject><dc:subject>inhibitors</dc:subject><dc:subject>antibacterial agents</dc:subject><dc:description>Bacterial resistance is an increasing threat to healthcare systems, highlighting the need for discovering new antibacterial agents. An established technique, fragment-based drug discovery, was used to target a bacterial enzyme Ddl involved in the biosynthesis of peptidoglycan. We assembled general and focused fragment libraries that were screened in a biochemical inhibition assay. Screening revealed a new fragment-hit inhibitor of DdlB with a Ki value of 20.7 ± 4.5 µM. Binding to the enzyme was confirmed by an orthogonal biophysical method, surface plasmon resonance, making the hit a promising starting point for fragment development.</dc:description><dc:date>2023</dc:date><dc:date>2022-12-06 10:53:47</dc:date><dc:type>Članek v reviji</dc:type><dc:identifier>142961</dc:identifier><dc:language>sl</dc:language></rdf:Description></rdf:RDF>
